Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance

Area of Science:

• Oncology
• Immunology
• Epigenetics
• Metabolism

Background:

• Tumor immune evasion is a complex process involving multiple regulatory layers, necessitating the identification of general driver genes.
• Malignant tumor diversity often limits the applicability of known immune evasion mechanisms to specific genetic and epigenetic contexts.

Purpose of the Study:

• To identify novel epitranscriptomic regulators involved in tumor immune evasion.
• To investigate the role of the m6A demethylase FTO in regulating tumor metabolism and immune surveillance.
• To evaluate the therapeutic potential of targeting FTO for cancer immunotherapy.

Main Methods:

• Identified FTO as a key regulator of immune evasion.
• Demonstrated FTO-mediated regulation of glycolytic metabolism via transcription factors c-Jun, JunB, and C/EBPβ.
• Utilized Fto knockdown to assess impact on tumor cell glycolysis and CD8+ T-cell function.
• Developed and tested the FTO inhibitor Dac51 in combination with checkpoint blockade therapy.

Main Results:

• FTO demethylation of m6A in tumor cells upregulates c-Jun, JunB, and C/EBPβ, leading to metabolic reprogramming.
• Fto knockdown reduces tumor cell glycolytic activity, enhancing CD8+ T-cell function and inhibiting tumor growth.
• The small-molecule inhibitor Dac51 effectively inhibits FTO activity, blocks immune evasion, and synergizes with checkpoint blockade for improved tumor control.

Conclusions:

• FTO is a critical epitranscriptomic regulator enabling tumor immune evasion through metabolic control.
• Targeting FTO and reprogramming the RNA epitranscriptome presents a promising strategy for enhancing cancer immunotherapy.
• Dac51 demonstrates potential as a therapeutic agent for blocking FTO-mediated immune evasion and improving anti-tumor responses.